NCT04594785|Unknown
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
RIPI
Loading search results
RIPI
Sponsor study identifier
observational
150
1 country
1
Study Start
October 1, 2020
Actual (reported)Primary Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions. Some of them are delayed and provide Post infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and PIIR have probably a suboptimal management. In this context the investigators aim to explore PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS invasive infections.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2020
Actual (reported)October 13, 2020
Actual (reported)October 20, 2020
Actual (reported)December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Describe the frequency PIIRs
Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection
1 day
Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection
1 day
Predictors of PIIRs
1 day
Pediatric population
Uhmontpellier
Montpellier, 34295, France
Eric JEZIORSKI
University Hospital, Montpellier
First Submitted
October 13, 2020
First Posted
October 20, 2020
Study Start
October 1, 2020
Actual (reported)Primary Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
Contact the study team to confirm eligibility.
Study Completion
December 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 28, 2020
Record last verified: 2020-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: